Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115650295 | 11565029 | 5 | F | 20150717 | 20160706 | 20150928 | 20160714 | EXP | US-EXELIXIS-CABO-15005567 | EXELIXIS | 64.64 | YR | M | Y | 0.00000 | 20160714 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115650295 | 11565029 | 1 | PS | COMETRIQ | CABOZANTINIB S-MALATE | 1 | Oral | 60 MG, QD | Y | U | L0406763, L0406689 | 203756 | 60 | MG | CAPSULE | QD | |||
| 115650295 | 11565029 | 2 | SS | COMETRIQ | CABOZANTINIB S-MALATE | 1 | Oral | 40 MG, QD | Y | U | L0406689, L0407290 | 203756 | 40 | MG | CAPSULE | QD | |||
| 115650295 | 11565029 | 3 | SS | COMETRIQ | CABOZANTINIB S-MALATE | 1 | Oral | 40 MG, QD | Y | U | 203756 | 40 | MG | CAPSULE | QD | ||||
| 115650295 | 11565029 | 4 | SS | COMETRIQ | CABOZANTINIB S-MALATE | 1 | Oral | 40 MG, QD | Y | U | 203756 | 40 | MG | CAPSULE | QD | ||||
| 115650295 | 11565029 | 5 | SS | FLEXERIL | CYCLOBENZAPRINE HYDROCHLORIDE | 1 | U | U | 0 | ||||||||||
| 115650295 | 11565029 | 6 | C | GABAPENTIN. | GABAPENTIN | 1 | U | 0 | |||||||||||
| 115650295 | 11565029 | 7 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | U | 0 | |||||||||||
| 115650295 | 11565029 | 8 | C | FUROSEMIDE. | FUROSEMIDE | 1 | U | 0 | |||||||||||
| 115650295 | 11565029 | 9 | C | TRAMADOL. | TRAMADOL | 1 | U | 0 | |||||||||||
| 115650295 | 11565029 | 10 | C | OXYCODONE | OXYCODONE | 1 | U | 0 | |||||||||||
| 115650295 | 11565029 | 11 | C | IMODIUM | LOPERAMIDE HYDROCHLORIDE | 1 | U | 0 | |||||||||||
| 115650295 | 11565029 | 12 | C | FRAGMIN | DALTEPARIN SODIUM | 1 | U | 0 | |||||||||||
| 115650295 | 11565029 | 13 | C | LOPERAMIDE | LOPERAMIDE | 1 | Y | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 115650295 | 11565029 | 1 | Thyroid cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 115650295 | 11565029 | OT |
| 115650295 | 11565029 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 115650295 | 11565029 | Aphasia | |
| 115650295 | 11565029 | Arteriovenous fistula thrombosis | |
| 115650295 | 11565029 | Arthralgia | |
| 115650295 | 11565029 | Bone pain | |
| 115650295 | 11565029 | Cataract | |
| 115650295 | 11565029 | Diarrhoea | |
| 115650295 | 11565029 | Eye disorder | |
| 115650295 | 11565029 | Fatigue | |
| 115650295 | 11565029 | Glossodynia | |
| 115650295 | 11565029 | Memory impairment | |
| 115650295 | 11565029 | Metabolic encephalopathy | |
| 115650295 | 11565029 | Myalgia | |
| 115650295 | 11565029 | Oral discomfort | |
| 115650295 | 11565029 | Orthostatic hypotension | |
| 115650295 | 11565029 | Palmar-plantar erythrodysaesthesia syndrome | |
| 115650295 | 11565029 | Vision blurred | |
| 115650295 | 11565029 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 115650295 | 11565029 | 1 | 20150619 | 20150828 | 0 | |
| 115650295 | 11565029 | 2 | 20150904 | 201603 | 0 | |
| 115650295 | 11565029 | 3 | 201603 | 201603 | 0 | |
| 115650295 | 11565029 | 4 | 201603 | 0 |